Rutgers, Cancer Institute of NJ

New Brunswick, New Jersey 08903

3 studies enrolling now · 18 studies all time

What they study most

AML, Acute GVHD, Acute-graft-versus-host Disease, Advanced Solid Malignancies, Advanced Solid Tumor, Carcinoma, Hepatocellular, Chronic Graft-versus-host-disease, Chronic Myelogenous Leukemia - Chronic Phase, Colorectal Neoplasms, ET (Essential Thrombocythemia), Endometrial Adenocarcinoma, Ewing Sarcoma

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Recruiting now
• Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies — Recruiting now
• XTX202 in Patients With Advanced Solid Tumors — Completed
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia — Completed
• ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) — Running, not enrolling
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors — Completed
• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients — Stopped early
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia — Running, not enrolling
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) — Completed
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors — Completed
• A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
• Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy — Completed
• Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors — Completed
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors — Completed
• Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) — Completed
• Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias — Stopped early